glp-1 drugs for weight loss side effects Do The Benefits of OutWeigh the Negatives? New research states weight loss

For patients already meeting indications for use of a GLP-1 drug based on metabolic factors, its potential role in lowering uveitis risk could be an added consideration when selecting antihyperglycemic therapy. 1 While these possibilities are positive advancements, a commentary on the study, also published yesterday in JAMA Ophthalmology , provides some potential limitations to keep in mind when interpreting conclusions

The frequency of bowel movements may increase or decrease compared to your baseline pattern

analysis [37], patients on GLP-1 RAs (exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, tirzepatide) had a significantly lower 1-year shunt placement rate (OR 0.375, 95% CI 0.1710.753, p = 0.047)

TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment.

Offers accountability and motivation

Get Free Access to Demo Report, Excel Pivot and ToC: Oral non-peptide GLP-1 receptor agonists represent a new generation of therapeutic agents designed to mimic the physiological activity of glucagon-like peptide-1 (GLP-1), a hormone that plays a critical role in regulating blood glucose levels, insulin secretion, gastric emptying, and appetite